Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1465)	10/27/1998 10:10:00 AM
From: Richard Huth	of 1491

Assuming that not everybody of you is familiar with German, I tried to find out who is behind the German newsgroup releasing information about PARS. Here is a short summary. The post was published by ACM (Arbeitsgemeinschaft Cannabis als Medizin e.V.), a non-profit organization. ACM is supporting the use of cannabis as a pharmaceutical drug. It was founded summer 1997 and has actually about 600 members (their statement), most of them doctors and patients. The article mentioned by you (Ariella) was a short summary of the results from PhII for HU-211 and the WSJ-article about its possible neuroprotective effect tested in rats which have been exposed to gas. The receivers of news published by ACM include doctors, at least on German review for doctors and interested people in several countries. Given the situation in Germany I would not expect a short term reaction in the stock price as a result of emerging interest. Compared to the US the investment culture in Germany is still underdeveloped, especially investing in stocks. A further hurdle will be that PARS is not listed on a German stock exchange. Foreign investments outside funds, big European players or well known US-stocks are not common, especially not in small, emerging companies like PARS (at least as long they are not "discovered" by the financial media). I was informed about a congress in Frankfurt (Germany) on Dec. 5th, where the keynote-speaker will concentrate about the possible use of dexanabinol and other synthetic analogs of marijuana. This should bring PARS into more minds. I asked them for more information about the congress. As soon as I have received them I will let you know about the details. Hope this was of interest to you, Richard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next